Lenvatinib

**Semantic type:** Pharmacologic Substance

**Definition:** A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.

**Synonyms:** - 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy- - E 7080 - E-7080 - E7080 - ER-203492-00 - LENVATINIB - Multi-Kinase Inhibitor E7080